Superpower BBB and Consumer-Complaint Trends: What the Data Actually Shows

Is Superpower a Legitimate Telehealth Company?

Superpower operates as a direct-to-consumer telehealth platform that bundles laboratory diagnostics, hormone therapy, GLP-1 agonist prescriptions, and peptide protocols under a single monthly membership. The company is not a licensed pharmacy. It works with affiliated compounding and retail pharmacies to fulfill prescriptions, which means the legitimacy question has multiple layers: corporate registration, clinical licensing, prescriber credentials, and pharmacy compliance.

Corporate and Business Registration

Superpower, Inc. Is registered as a corporation in Delaware, which is a standard legal structure for venture-backed U.S. Health-tech companies. Delaware incorporation alone says nothing about clinical quality. What matters more is whether the medical professional corporation (PC) or professional association (PA) operating behind the consumer-facing brand holds active state telehealth licenses wherever it accepts patients.

The Federation of State Medical Boards maintains an online database of disciplinary actions against physicians. As of the research date for this article, no disciplinary entries matching Superpower's named medical directors appear in the FSMB Physician Data Center, though that database covers only physician-level discipline and not organizational-level complaints.

LegitScript Status

LegitScript is an independent verification and monitoring service that the FDA and major payment processors use as a proxy for pharmacy and telehealth legitimacy. LegitScript's Healthcare Merchant Standards require compliant telehealth platforms to demonstrate valid prescriber licensing, compliant pharmacy partnerships, and transparent pricing. Superpower does not appear in LegitScript's publicly searchable list of certified telehealth providers as of July 2025. That absence is not the same as a violation finding. Many legitimate telehealth companies have not pursued LegitScript certification. Still, it is a data point worth weighing.

FDA Regulatory Standing

The FDA's publicly searchable Warning Letters database shows no warning letters addressed to Superpower or its affiliated pharmacies as of this writing. The FDA did issue a January 2025 guidance clarifying compound semaglutide's status after removing semaglutide from the drug shortage list, signaling that compounded semaglutide would face renewed scrutiny. Any platform currently offering compounded semaglutide should demonstrate that its pharmacy partners have pivoted or are in a documented transition plan.

Superpower BBB Profile and Complaint Volume

The Better Business Bureau is not a government regulator. Its ratings reflect a formula that weights complaint volume, complaint resolution, and business responsiveness. A high BBB rating does not guarantee a high-quality clinical service, and a low rating does not always mean fraud. With that context, here is what the BBB record shows.

Current BBB Rating and Accreditation

Superpower holds no BBB accreditation as of July 2025. Accreditation is a paid, voluntary program. Its absence means the company has not applied or has not met BBB's accreditation standards, not necessarily that it has been rejected. Unaccredited companies can still have BBB profiles built from consumer submissions.

The BBB profile for Superpower shows a rating that has fluctuated based on complaint closure patterns. BBB grades companies on a 13-point scale (A+ through F), weighting unresolved complaints most heavily. Complaint patterns at companies in the direct-to-consumer GLP-1 space often cluster around three categories: (1) billing disputes after a free-trial or discounted onboarding period, (2) difficulty canceling memberships, and (3) delays between consultation and prescription delivery.

Dominant Complaint Themes

Based on publicly posted BBB consumer narratives for Superpower and comparable telehealth brands in the GLP-1 and hormone-therapy space, four themes appear repeatedly.

Billing transparency. Consumers report unexpected charges after a promotional introductory period. The FTC's Negative Option Rule, updated in 2023, requires that subscription services clearly disclose recurring charges before enrollment and provide a simple cancellation mechanism. Complaints that cite unauthorized recurring charges are a signal worth monitoring.

Prescription turnaround. Telehealth GLP-1 prescriptions require a licensed prescriber review and, in some states, an asynchronous chart review that takes 24 to 72 hours. Complaints in this category usually reflect a mismatch between the company's marketed speed and operational reality, not necessarily clinical negligence. Delays in GLP-1 initiation carry real clinical cost for patients managing obesity or type 2 diabetes.

Compounded medication concerns. The FDA's 2024-2025 actions on compounded semaglutide and tirzepatide have created supply-chain turbulence across the sector. Some consumer complaints reference receiving products from 503A compounding pharmacies rather than the FDA-regulated 503B outsourcing facilities, a distinction that matters for product sterility and dosing accuracy. The FDA outlines these differences in its compounding oversight guidance.

Customer service responsiveness. A recurring thread involves slow or unresponsive support after a prescription issue arises. This is an operational problem rather than a safety problem, but it becomes a safety issue when a patient cannot reach a clinician to report a side effect or adjust a dose.

How Superpower's Complaint Rate Compares to the Sector

Putting any single brand's complaint volume in context requires a denominator: how many active subscribers does the platform have? Superpower has not published subscriber counts. Hims and Hers Health (HIMS), a publicly traded telehealth company with overlapping GLP-1 and hormone-therapy offerings, reported approximately 2.2 million active subscribers in Q1 2025 in its SEC filings. Its BBB profile shows several hundred complaints over a rolling 36-month window, yielding a complaint rate well below 0.1% of the subscriber base. That rate is the sector's rough benchmark for a platform operating at scale.

Superpower's complaint count is smaller in absolute terms, which may reflect a smaller subscriber base rather than superior operations. Without an enrollment denominator, complaint counts alone are difficult to interpret.

The framework below summarizes a five-factor approach any patient can use to independently assess a direct-to-consumer hormone or GLP-1 telehealth brand before subscribing. HealthRX medical staff developed this rubric based on FTC guidance, FDA compounding policy, and FSMB telehealth standards.

| Factor | What to Check | Source | |---|---|---| | 1. Prescriber licensing | Verify the named prescriber in your state's medical board lookup | State medical board website | | 2. Pharmacy type | 503A vs. 503B compounder; 503B preferred for injectables | FDA outsourcing facility list | | 3. LegitScript status | Certified, not certified, or listed as rogue | LegitScript.com | | 4. FTC compliance | Clear cancellation path, no hidden fees | FTC Negative Option Rule | | 5. BBB complaint pattern | Look at complaint type, not just count | BBB.org company profile |

Superpower's Clinical Model: What It Offers and Where the Evidence Sits

Superpower markets a "comprehensive optimization" approach that combines biomarker testing, GLP-1 therapy, testosterone replacement, and peptide protocols. Each of these categories carries a distinct evidence profile.

GLP-1 Agonists

Semaglutide 2.4 mg (Wegovy) produced 14.9% mean body weight loss at 68 weeks versus 2.4% for placebo in STEP-1 (N=1,961), published in the New England Journal of Medicine in 2021. Wilding et al., NEJM 2021. Tirzepatide 15 mg produced 20.9% mean weight loss at 72 weeks in SURMOUNT-1 (N=2,539). Jastreboff et al., NEJM 2022. These are the two best-supported options in this class. Both carry FDA approval for chronic weight management.

The evidence for compounded versions of these drugs is thinner. Compounded semaglutide and tirzepatide have not undergone the same Phase 3 clinical trials as branded Ozempic, Wegovy, or Mounjaro. The FDA explicitly noted in its February 2025 statement that "FDA has received reports of adverse events, including hospitalizations, associated with the use of compounded semaglutide." That warning should appear in any honest consent process.

Testosterone Replacement Therapy

The Endocrine Society's 2018 clinical practice guideline recommends TRT for men with confirmed hypogonadism, defined as a total testosterone below 300 ng/dL on two morning measurements combined with signs and symptoms. Bhasin et al., J Clin Endocrinol Metab 2018. The guideline specifically cautions against TRT in men who are trying to conceive, given spermatogenesis suppression.

A telehealth TRT program that does not obtain two fasting morning serum testosterone values before prescribing, or does not screen for hematocrit, PSA, and cardiovascular risk, falls short of this standard. Patients should ask the prescriber directly which labs are collected and at what intervals.

Peptides

This category carries the weakest regulatory and evidence footing. Peptides such as BPC-157, TB-500, and CJC-1295/Ipamorelin are not FDA-approved drugs. The FDA has removed several from the list of bulk substances that compounders may use. The agency's 2023 policy update on peptides removed BPC-157 and several other peptides from the permissible 503A bulk drug list, meaning compounding pharmacies cannot legally make them for sale in the U.S. Any telehealth brand currently offering these specific peptides deserves direct questions about which pharmacy is supplying them and under what regulatory authority.

What State Regulators and Attorneys General Are Watching

State-level oversight of telehealth brands has accelerated since 2023. Several state attorneys general, including those in Texas, California, and New York, have opened investigations or issued subpoenas related to compounded GLP-1 marketing practices, though public enforcement actions remain limited as of mid-2025.

Telehealth Prescribing Standards

The Federation of State Medical Boards' 2020 Model Policy for the Appropriate Use of Telemedicine requires that telehealth prescribers establish a valid patient-physician relationship, which in most states means a synchronous video or audio visit before prescribing controlled substances or Schedule III agents. Testosterone is Schedule III. GLP-1 agonists are not scheduled, but most state boards expect at minimum a documented clinical evaluation before prescribing.

Platforms that offer asynchronous-only consultations for Schedule III prescriptions may be operating outside their licensing authority in certain states. Ask whether your initial visit is synchronous (live video or phone) or asynchronous (questionnaire only).

FTC Enforcement on Subscription Health Services

The FTC's updated Negative Option Rule (16 CFR Part 425), finalized in 2024, imposes specific disclosure requirements on subscription wellness services. The rule requires that a company disclose the subscription price and renewal terms before the consumer submits payment, provide a single-step online cancellation mechanism, and not charge for an additional period after cancellation is requested. Violations carry civil penalties up to $51,744 per violation as of 2024 FTC penalty updates. Consumers who believe a telehealth subscription violated these terms can file a complaint at FTC.gov/complaint.

Red Flags vs. Expected Friction in Telehealth

Not every consumer complaint reflects a defective company. Some friction is inherent to regulated healthcare. The table below distinguishes complaints that signal a systemic problem from those that reflect the normal complexity of telehealth prescribing.

| Complaint Type | Likely Signal | Action | |---|---|---| | "My prescription took 5 days to process" | Normal operational friction | Low concern; verify your state's telemedicine rules | | "I was charged after I canceled" | Potential FTC/Negative Option Rule violation | File FTC complaint; dispute with credit card issuer | | "I received unlabeled vials" | Pharmacy compliance concern | Contact your state pharmacy board; report to FDA MedWatch | | "The peptide I ordered is now unavailable" | FDA policy change (normal) | Verify with FDA bulk drug substance list | | "My prescriber is not licensed in my state" | Regulatory violation | File complaint with your state medical board | | "Side effects were not mentioned during consult" | Consent process failure | Contact your state medical board and file an FDA MedWatch report |

How to File a Complaint Against a Telehealth Brand

If you have a substantiated concern about Superpower or any similar platform, there are four distinct channels that carry different investigative weight.

Better Business Bureau

The BBB complaint process at bbb.org is consumer-facing and voluntary. BBB complaints are visible publicly and appear in the company's rating calculation. The BBB can support mediation but has no enforcement authority.

Federal Trade Commission

FTC complaints at ftc.gov/complaint feed the Consumer Sentinel Network, a database shared with state attorneys general and over 2,800 law-enforcement agencies. A billing dispute that affects multiple consumers may trigger an FTC investigation once complaint volume crosses an internal threshold. Individual complaints are not investigated individually.

FDA MedWatch

Adverse events or product quality concerns related to a compounded medication should be reported via FDA MedWatch. Reports of unlabeled vials, inconsistent dosing, or particulate matter in injectable products should go here, not to the BBB.

State Medical Board

If the core complaint involves a prescriber's clinical conduct, including prescribing without an adequate evaluation, failing to obtain informed consent, or practicing across state lines without licensure, the appropriate channel is your state medical board. The FSMB maintains a directory of state medical boards.